201 related articles for article (PubMed ID: 36843668)
1. Potential New Approaches for Prostate Cancer Management in Resource-Limited Countries in Africa.
Bosland MC; Shittu OB; Ikpi EE; Akinloye O
Ann Glob Health; 2023; 89(1):14. PubMed ID: 36843668
[TBL] [Abstract][Full Text] [Related]
2. Global viewpoints: updates on prostate cancer in Sub-Saharan Africa.
Jalloh M; Cassell A; Niang L; Rebbeck T
BJU Int; 2024 Jan; 133(1):6-13. PubMed ID: 37702258
[TBL] [Abstract][Full Text] [Related]
3. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
4. Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer.
Bello JO
BMC Urol; 2017 May; 17(1):39. PubMed ID: 28558685
[TBL] [Abstract][Full Text] [Related]
5. Prostate Cancer Screening, Diagnostic, Treatment Procedures and Costs in Sub-Saharan Africa: A Situational Analysis.
Makau-Barasa LK; Manirakiza A; Carvalho AL; Rebbeck TR
Cancer Control; 2022; 29():10732748221084932. PubMed ID: 35350915
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
7. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
8. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen and androgen deprivation therapy.
Ruckle HC; Oesterling JE
World J Urol; 1993; 11(4):227-32. PubMed ID: 7508789
[TBL] [Abstract][Full Text] [Related]
10. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
11. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
12. Management Options for Biochemically Recurrent Prostate Cancer.
Fakhrejahani F; Madan RA; Dahut WL
Curr Treat Options Oncol; 2017 May; 18(5):26. PubMed ID: 28434181
[TBL] [Abstract][Full Text] [Related]
13. Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study.
Seraphin TP; Joko-Fru WY; Hämmerl L; Griesel M; Mezger NCS; Feuchtner JC; Adoubi I; Egué MD; Okerosi N; Wabinga H; Hansen R; Vuma S; Lorenzoni C; Coulibaly B; Odzebe SW; Buziba NG; Aynalem A; Liu B; Medenwald D; Mikolajczyk RT; Efstathiou JA; Parkin DM; Jemal A; Kantelhardt EJ
Cancer; 2021 Nov; 127(22):4221-4232. PubMed ID: 34328216
[TBL] [Abstract][Full Text] [Related]
14. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
15. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
16. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
17. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
Mukherji D; Youssef B; Dagher C; El-Hajj A; Nasr R; Geara F; Rabah D; Al Dousari S; Said R; Ashou R; Wazzan W; Jabbour M; Farha G; Al Hamdani N; Al Hallaq Y; Ghazal H; Dbouk H; Bachir B; El Khoury C; Sakr G; Hussain HK; Sayyid K; Ibrahim K; Haidar M; Zouain N; Bitar N; Alameh W; Abbas F; Faddoul S; Nemer E; Assaf G; Farhat F; Bulbul M; Temraz S; Shamseddine A; Gillessen S; Omlin A; Khauli R
World J Urol; 2020 Mar; 38(3):681-693. PubMed ID: 31297628
[TBL] [Abstract][Full Text] [Related]
18. Barriers to Prostate Cancer Screening by Men in Sub-Saharan Africa: An Integrated Review.
Baratedi WM; Tshiamo WB; Mogobe KD; McFarland DM
J Nurs Scholarsh; 2020 Jan; 52(1):85-94. PubMed ID: 31733043
[TBL] [Abstract][Full Text] [Related]
19. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
20. The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT
Urol Clin North Am; 1999 May; 26(2):263-73. PubMed ID: 10361549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
